ES2162815T3 - Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de agonistas de acido gamma-aminobutirico (gaba). - Google Patents

Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de agonistas de acido gamma-aminobutirico (gaba).

Info

Publication number
ES2162815T3
ES2162815T3 ES93907540T ES93907540T ES2162815T3 ES 2162815 T3 ES2162815 T3 ES 2162815T3 ES 93907540 T ES93907540 T ES 93907540T ES 93907540 T ES93907540 T ES 93907540T ES 2162815 T3 ES2162815 T3 ES 2162815T3
Authority
ES
Spain
Prior art keywords
chloro
pharmaceutically acceptable
acceptable salt
gaba
gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93907540T
Other languages
English (en)
Inventor
Mussie Elizabeth Wolde
Guadalupe Ruiz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2162815T3 publication Critical patent/ES2162815T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE PRESENTAN COMPOSICONES OFTALMICAS Y UN METODO PARA EL TRATAMIENTO DEL GLAUCOMA Y/O HIPERTENSION OCULAR EN EL OJO DE LOS MAMIFEROS MEDIANTE LA ADMINISTRACION AL OJO DEL MAMIFERO DE LA COMPOSICION OFTALMICA DE LA INVENCION, QUE CONTIENE COMO INGREDIENTE ACTIVO UNO O MAS COMPUESTOS AGONISTAS DE ACIDO GAMMA AMINOBUTIRICO. EJEMPLOS DE AGONISTAS DEL ACIDO GAMMA AMINOBUTIRICO UTILIZADO EN LA COMPOSICION OFTALMICA Y METODOS DE TRATAMIENTO SON: ACIDO GAMMA AMINO BUTIRICO (GABA), 5-(AMINOMETIL)-3(2H)-ISOXAZOLONA MUSCIMOL, 4,5,6,7TETRAHIDROISOXAZOLO[5,4-C]PIRIDIN-3-OL (THIP) Y UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL 4,5,6,7-TETRAHIDROISOXAZOLO[5,4C]PIRIDIN-3-OL, ACIDO PIPERIDINA-4-SULFONICO Y UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL ACIDO PIPERIDINA-4-SULFONICO, 3-(2H)ISOTIAZOLONA, 5-(AMINOMETIL)(TIOMUSCIMOL), 7-CLORO-1,3-DIHIDRO-1METIL-5-FENIL-2H-1,4-BENZODIAZEPIN-2-ONA (DIAZEPAM), 7-CLORO-1-[2(DIETILAMINO)ETIL]-5-(FLUOROFENIL)-1,3-DIHIDRO-2H-1,4BENZODIAZAEPINA-2-ONA (FLURAZEPAM) Y UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL 7-CLORO-1-[2-(DIETILAMINO)ETIL]-5-(FLUOROFENIL)-1,3DIHIDRO-2H-1,4-BENZODIAZEPINA-2-ONA, Y 4-OXIDO 7-CLORO-N-METIL-5FENIL-3H-1,4-BENZODIAZEPINA-2-AMINA (CLORDIAZEPOXIDO) Y UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL 4 OXIDO 7-CLORO-N-METIL-5-FENIL-3H1,4-BENZODIAZEPINA-2-AMINA.
ES93907540T 1992-03-19 1993-03-16 Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de agonistas de acido gamma-aminobutirico (gaba). Expired - Lifetime ES2162815T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/856,012 US6077839A (en) 1992-03-19 1992-03-19 Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists

Publications (1)

Publication Number Publication Date
ES2162815T3 true ES2162815T3 (es) 2002-01-16

Family

ID=25322685

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93907540T Expired - Lifetime ES2162815T3 (es) 1992-03-19 1993-03-16 Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de agonistas de acido gamma-aminobutirico (gaba).

Country Status (9)

Country Link
US (1) US6077839A (es)
EP (1) EP0630240B1 (es)
JP (1) JPH07505156A (es)
AT (1) ATE205392T1 (es)
AU (1) AU3810893A (es)
CA (1) CA2132102A1 (es)
DE (1) DE69330749T2 (es)
ES (1) ES2162815T3 (es)
WO (1) WO1993018762A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736514B2 (en) * 1995-07-13 2001-07-26 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Non-allosteric gabaa agonists for treating sleep disorders
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
AU7405000A (en) * 1999-09-28 2001-04-30 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
EP1363605A1 (de) * 2001-02-13 2003-11-26 Dr. Gerhard Mann Chem.-Pharm. Fabrik GmbH Gaba-rezeptor-modulatoren zur behandlung neurodegenerativer erkrankungen des auges
US20040242457A1 (en) * 2003-05-27 2004-12-02 Ashby Charles R. Use of anti-glaucoma drugs to treat visual defects associated with the use of a GABAergic agent
EP2309858A4 (en) 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2011113904A1 (en) * 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
US8784835B2 (en) * 2012-07-02 2014-07-22 Trent Austin Method for producing muscimol and/or reducing ibotenic acid from amanita tissue

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467756A (en) * 1967-03-16 1969-09-16 Merck & Co Inc Composition and method for treating glaucoma
US3644643A (en) * 1969-10-13 1972-02-22 Unimed Inc Method of reducing intraocular pressure using glycine
US4363818A (en) * 1975-06-04 1982-12-14 Gottlieb Sheldon K Method for relief of burning, itching, and pain of cutaneous and mucosal surfaces
US4171377A (en) * 1978-08-11 1979-10-16 Burton, Parsons & Co., Inc. Ophthalmic solution of tranexamic acid
US4197301A (en) * 1978-10-16 1980-04-08 Allergan Pharmaceuticals, Inc. Topical ophthalmic use of Prazosin
US4322440A (en) * 1980-06-25 1982-03-30 New York University Anticonvulsive compositions and method of treating convulsive disorders
US4565821A (en) * 1983-03-21 1986-01-21 The Texas A&M University System Method and ophthalmic composition for treating ocular hypertension and glaucoma with butyrophenones
US4837021A (en) * 1986-12-31 1989-06-06 Laboratoires P.O.S. Two part tissue irrigating solution
US5066664A (en) * 1990-02-28 1991-11-19 Allergan, Inc. 2-(hydroxy-2-alkylphenylamino)-oxazolines and thiazolines as anti-glaucoma and vasoconstrictive agents
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents

Also Published As

Publication number Publication date
AU3810893A (en) 1993-10-21
WO1993018762A3 (en) 1993-10-28
CA2132102A1 (en) 1993-09-30
DE69330749D1 (de) 2001-10-18
JPH07505156A (ja) 1995-06-08
EP0630240A1 (en) 1994-12-28
ATE205392T1 (de) 2001-09-15
EP0630240B1 (en) 2001-09-12
US6077839A (en) 2000-06-20
DE69330749T2 (de) 2002-07-04
WO1993018762A2 (en) 1993-09-30

Similar Documents

Publication Publication Date Title
RU2219167C2 (ru) N-замещенные аминотетралины как лиганды для рецептора y5 нейропептида y, полезные при лечении ожирения и других расстройств
ATE195117T1 (de) 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
NO964939D0 (no) Fremgangsmåte for fremstilling av virkestoffpreparater i form av en fast lösning av virkestoffet i en polymermatriks, samt virkestoffpreparater fremstilt ved hjelp av denne fremgangsmåte
ES2162815T3 (es) Metodo para reducir la presion intraocular en el ojo de mamiferos por administracion de agonistas de acido gamma-aminobutirico (gaba).
AU3330495A (en) N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4- benzodiazepines
FR2755967B1 (fr) Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
KR930001913A (ko) 안염 치료방법
CA2431982A1 (en) Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
DK1149579T3 (da) Anvendelse af en östrogenagonist/antagonist til behandling af seksualforstyrrelse hos kvinder
IL127717A (en) History of useful convulsions in the treatment of amyotrophic lateral sclerosis (ALS)
AR035158A1 (es) Inhibidores de recaptacion de norepinefrina altamente selectivos y metodo para usar los mismos
KR950704311A (ko) 물질 p 길항체로서의 퀴누클리딘 유도체(quinuclidine derivative as substance p antagonist)
LU90969I2 (fr) Compositions ophtalmiques topiques contenant olopatadine destinees au tritement d'affections allergiques des yeux
WO2001010846A3 (en) 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
WO2002009702A8 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
CZ285008B6 (cs) 2,3-dihydro-1-(2,2,2-trifluorethyl)-2-oxo-5-fenyl-1H-1,4-benzodiazepinové deriváty a farmaceutický prostředek s jejich obsahem
KR950701223A (ko) 항허혈성(Anti-ichemic)약물
JP2001521500A (ja) 緑内障に関連する視神経変性を防止する薬剤の製造におけるナトリウムチャンネル遮断剤の使用
PT838223E (pt) Inibidor do edema cerebral
AU609807B2 (en) A composition for the topical treatment of glaucoma or ocular hypertension
ES2145823T3 (es) Agente para la profilaxis o el tratamiento de cataratas.
US5190962A (en) Treating hypertension
WO1995034302A3 (en) Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
US5198436A (en) Intraoral dosing method of administering trifluorobenzodiazepines
BR0209601A (pt) Método para o tratamento da hipertensão ocular e do glaucoma

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 630240

Country of ref document: ES